Study Design Type: Phase 2, double-blind, randomized, placebo-controlled study Participants: 338 adults (BMI 30 or BMI 27 with a coexisting condition) Groups: Retatrutide 1 mg, 4 mg, 8 mg, 12 mg (different initial doses 2 or 4 mg) and placebo Duration: 48 weeks (plus 4 weeks follow-up) Administration: subcutaneous, 1x weekly Primary endpoint: percentage change in body weight at week 24 Secondary endpoints: change in weight at week 48, 5%, 10%, 15% weight reduction
Here, we therefore investigated the skin-whitening and skin-condition effects of the topical application of GSSG in healthy female subjects
Liver failure happens when your liver starts to shut down
Contact your insurer to find out if it excludes weight loss injectables from coverage
ATP7A-related copper transport disorders: A systematic review and definition of the clinical subtypes
Mechanistic Research Perspective Regulation of neural cellular signaling pathways Modulation of gene expression associated with circadian rhythms Influence on mitochondrial energy balance within neural cells Interaction with stress-responsive peptide networks Analysis of peptide signaling integration in neural and endocrine systems Primary Research Applications Neurochemical Signaling Analysis: Used in experimental models studying neurotransmitter pathways and peptide-mediated neural communication
